scispace - formally typeset
Search or ask a question
Institution

Charité

HealthcareBerlin, Germany
About: Charité is a healthcare organization based out in Berlin, Germany. It is known for research contribution in the topics: Population & Transplantation. The organization has 30624 authors who have published 64507 publications receiving 2437322 citations. The organization is also known as: Charite & Charité – University Medicine Berlin.


Papers
More filters
Journal ArticleDOI
TL;DR: It is demonstrated that IL‐22, in contrast to its relative IFN‐γ, regulates the expression of only a few genes in keratinocytes, which may be important in the innate immunity and reorganization of epithelia.
Abstract: IL-22 is an IFN-IL-10 cytokine family member, which is produced by activated Th1 and NK cells and acts primarily on epithelial cells. Here we demonstrate that IL-22, in contrast to its relative IFN-gamma, regulates the expression of only a few genes in keratinocytes. This is due to varied signal transduction. Gene expressions regulated by IL-22 should enhance antimicrobial defense [psoriasin (S100A7), calgranulin A (S100A8), calgranulin B (S100A9)], inhibit cellular differentiation (e.g., profilaggrin, keratins 1 and 10, kallikrein 7), and increase cellular mobility [e.g., matrix metalloproteinease 1 (MMP1, collagenase 1), MMP3 (stromelysin 1), desmocollin 1]. In contrast, IFN-gamma favored the expression of MHC pathway molecules, adhesion molecules, cytokines, chemokines, and their receptors. The IL-22 effects were transcriptional and either independent of protein synthesis and secretion, or mediated by a secreted protein. Inflammatory conditions, but not keratinocyte differentiation, amplified the IL-22 effects. IL-22 application in mice enhanced cutaneous S100A9 and MMP1 expression. High IL-22 levels in psoriatic skin were associated with strongly up-regulated cutaneous S100A7, S100A8, S100A9, and MMP1 expression. Psoriatic patients showed strongly elevated IL-22 plasma levels, which correlated with the disease severity. Expression of IL-22 and IL-22-regulated genes was reduced by anti-psoriatic therapy. In summary, despite similarities, IFN-gamma primarily amplifies inflammation, while IL-22 may be important in the innate immunity and reorganization of epithelia.

918 citations

Journal ArticleDOI
TL;DR: The present data provide Level 2b evidence (Oxford Centre for Evidence-based Medicine) that survival depends on complete resection of enhancing tumor in glioblastoma multiforme and treatment bias was demonstrated regarding resection and second-line therapies.
Abstract: Treatment bias was demonstrated regarding resection and second-line therapies. However, bias and imbalances were controllable in the cohorts available from the 5-aminolevulinic acid study so that the present data now provide Level 2b evidence (Oxford Centre for Evidence-based Medicine) that survival depends on complete resection of enhancing tumor in glioblastoma multiforme.

917 citations

Journal ArticleDOI
Gerald B. Appel1, Gabriel Contreras2, Mary Anne Dooley3, Ellen M. Ginzler4, David A. Isenberg5, David Jayne6, Lei Shi Li, Eduardo Mysler, Jorge Sánchez-Guerrero, Neil Solomons, David Wofsy7, Carlos Abud, Sharon G. Adler8, Graciela S. Alarcón9, Elisa N. Albuquerque10, Fernando Almeida, Alejandro Alvarellos, Gerald B. Appel1, Hilario Avila11, Cornelia Blume12, Ioannis Boletis, Alain Bonnardeaux, Alan Braun, Jill P. Buyon13, Ricard Cervera14, Nan Chen15, Shun-Le Chen15, António Gomes Da Costa16, Razeen Davids17, David D'Cruz18, Enrique de Ramón, Atul Deodhar19, Andrea Doria20, Bertrand Dussol, Paul Emery21, Justus Fiechtner, Jürgen Floege, Hilda Fragoso-Loyo, Richard Furie22, Rozina Ghazalli23, Cybele Ghossein23, Gary S. Gilkeson24, EM Ginzler25, Caroline Gordon8, Jennifer M. Grossman8, Jieruo Gu26, Loïc Guillevin, Pierre Yves Hatron27, Gisela Herrera28, Falk Hiepe28, Frédéric Houssiau, Osvaldo Hübscher, Claudia Hura29, Joshua Kaplan30, Gianna Mastroianni Kirsztajn30, Emese Kiss31, Ghazali Ahmad Kutty, Maurice Laville, Maria Lazaro, Oliver Lenz2, Leishi Li32, Liz Lightstone33, Sam Lim34, Michel Malaise35, Susan Manzi35, Juan Carlos Marcos, Olivier Meyer36, Pablo Monge37, Saraladev Naicker37, Nathaniel Neal38, Michael Neuwelt39, Kathy Nicholls40, Nancy J. Olsen40, José Ordi-Ros41, Barbara E. Ostrov42, Manuel Pestana43, Michelle Petri44, G. Pokorny44, Jacques Pourrat15, Jiaqi Qian15, Jai Radhakrishnan1, Brad H. Rovin, Julio Sanchez Roman, Joseph C. Shanahan45, William Shergy, Fotini Skopouli, Alberto Spindler46, Christopher Striebich47, Robert Sundel48, Charles R. Swanepoel48, Yen Tan Si49, Guillermo Tate, Vladimír Tesaŕ37, Mohamed Tikly37, Haiyan Wang, Rosnawati Yahya50, Xueqing Yu26, Fengchun Zhang50, Diana Zoruba 
Columbia University1, University of Miami2, University of North Carolina at Chapel Hill3, SUNY Downstate Medical Center4, University College London5, Cambridge University Hospitals NHS Foundation Trust6, University of California, San Francisco7, University of California, Los Angeles8, University of Alabama at Birmingham9, Rio de Janeiro State University10, University of Guadalajara11, University of Düsseldorf12, New York University13, University of Barcelona14, Shanghai Jiao Tong University15, University of Lisbon16, Stellenbosch University17, Guy's and St Thomas' NHS Foundation Trust18, Oregon Health & Science University19, University of Padua20, University of Leeds21, North Shore-LIJ Health System22, Northwestern University23, Medical University of South Carolina24, University of Birmingham25, Sun Yat-sen University26, Lille University of Science and Technology27, Charité28, Rutgers University29, Federal University of São Paulo30, University of Debrecen31, Imperial College London32, Emory University33, University of Liège34, University of Pittsburgh35, University of Paris36, University of the Witwatersrand37, California State University, Long Beach38, Royal Melbourne Hospital39, University of Texas Southwestern Medical Center40, Autonomous University of Barcelona41, Pennsylvania State University42, Johns Hopkins University43, University of Szeged44, Duke University45, University of Colorado Denver46, Harvard University47, University of Cape Town48, University of Malaya49, Peking Union Medical College50
TL;DR: Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Abstract: Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.

909 citations

Journal ArticleDOI
TL;DR: If the long-term oncological results of Laparoscopic and conventional resection of colonic carcinoma show equivalent results, the laparoscopic approach should be preferred in patients suitable for this approach to colectomy.
Abstract: Background Colorectal resections are common surgical procedures all over the world. Laparoscopic colorectal surgery is technically feasible in a considerable amount of patients under elective conditions. Several short-term benefits of the laparoscopic approach to colorectal resection (less pain, less morbidity, improved reconvalescence and better quality of life) have been proposed. Objectives This review compares laparoscopic and conventional colorectal resection with regards to possible benefits of the laparoscopic method in the short-term postoperative period (up to 3 months post surgery). Search methods We searched MEDLINE, EMBASE, CancerLit, and the Cochrane Central Register of Controlled Trials for the years 1991 to 2004. We also handsearched the following journals from 1991 to 2004: British Journal of Surgery, Archives of Surgery, Annals of Surgery, Surgery, World Journal of Surgery, Disease of Colon and Rectum, Surgical Endoscopy, International Journal of Colorectal Disease, Langenbeck's Archives of Surgery, Der Chirurg, Zentralblatt fur Chirurgie, Aktuelle Chirurgie/Viszeralchirurgie. Handsearch of abstracts from the following society meetings from 1991 to 2004: American College of Surgeons, American Society of Colorectal Surgeons, Royal Society of Surgeons, British Assocation of Coloproctology, Surgical Association of Endoscopic Surgeons, European Association of Endoscopic Surgeons, Asian Society of Endoscopic Surgeons. Selection criteria All randomised-controlled trial were included regardless of the language of publication. No- or pseudorandomised trials as well as studies that followed patient's preferences towards one of the two interventions were excluded, but listed separately. RCT presented as only an abstract were excluded. Data collection and analysis Results were extracted from papers by three observers independently on a predefined data sheet. Disagreements were solved by discussion. 'REVMAN 4.2' was used for statistical analysis. Mean differences (95% confidence intervals) were used for analysing continuous variables. If studies reported medians and ranges instead of means and standard deviations, we assumed the difference of medians to be equal to the difference of means. If no measure of dispersion was given, we tried to obtain these data from the authors or estimated SD as the mean or median. Data were pooled and rate differences as well as weighted mean differences with their 95% confidence intervals were calculated using random effects models. Main results 25 RCT were included and analysed. Methodological quality of most of these trials was only moderate and perioperative treatment was very traditional in most studies. Operative time was longer in laparscopic surgery, but intraoperative blood was less than in conventional surgery. Intensity of postoperative pain and duration of postoperative ileus was shorter after laparoscopic colorectal resection and pulmonary function was improved after a laparoscopic approach. Total morbidity and local (surgical) morbidity was decreased in the laparoscopic groups. General morbidity and mortality was not different between both groups. Until the 30th postoperative day, quality of life was better in laparoscopic patients. Postoperative hospital stay was less in laparoscopic patients. Authors' conclusions Under traditional perioperative treatment, lapararoscopic colonic resections show clinically relevant advantages in selected patients. If the long-term oncological results of laparoscopic and conventional resection of colonic carcinoma show equivalent results, the laparoscopic approach should be preferred in patients suitable for this approach to colectomy.

907 citations


Authors

Showing all 30787 results

NameH-indexPapersCitations
JoAnn E. Manson2701819258509
Yi Chen2174342293080
David J. Hunter2131836207050
Raymond J. Dolan196919138540
John P. A. Ioannidis1851311193612
Stefan Schreiber1781233138528
Kenneth C. Anderson1781138126072
Eric J. Nestler178748116947
Klaus Rajewsky15450488793
Charles B. Nemeroff14997990426
Andreas Pfeiffer1491756131080
Rinaldo Bellomo1471714120052
Jean Bousquet145128896769
Christopher Hill1441562128098
Holger J. Schünemann141810113169
Network Information
Related Institutions (5)
Ludwig Maximilian University of Munich
161.5K papers, 5.7M citations

93% related

Heidelberg University
119.1K papers, 4.6M citations

92% related

Johns Hopkins University School of Medicine
79.2K papers, 4.7M citations

92% related

Brigham and Women's Hospital
110.5K papers, 6.8M citations

92% related

Mayo Clinic
169.5K papers, 8.1M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202339
2022317
20214,865
20204,577
20194,042
20183,718